世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
膵臓がん診断 - 世界市場シェア・ランキング、全体売上高・需要予測 2024-2030Pancreatic Cancer Diagnosis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 膵臓癌診断の世界市場は、2023年には100万米ドル規模と推定され、2024〜2030年の予測期間中のCAGRは%で、2030年には100万米ドルに再調整されると予測されている。 世界の医薬品市場は2022年に1,475億米ドルとな... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー膵臓癌診断の世界市場は、2023年には100万米ドル規模と推定され、2024〜2030年の予測期間中のCAGRは%で、2030年には100万米ドルに再調整されると予測されている。世界の医薬品市場は2022年に1,475億米ドルとなり、今後6年間のCAGRは5％で成長する。医薬品市場には化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億米ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間＆政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要としている患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の流行はワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。 レポートの範囲 本レポートは、膵臓がん診断の世界市場を包括的に紹介することを目的としており、地域別・国別、タイプ別、用途別の膵臓がん診断の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てている。 膵臓がん診断の市場規模、推計、予測は、2023年を基準年とし、2019年から2030年までの期間の履歴データと予測データを売上高（百万ドル）で提供しています。定量分析および定性分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、膵臓がん診断に関する情報に基づいたビジネス上の意思決定を行うことを支援します。 市場区分 企業別 エフ・ホフマン・ラ・ロシュAG メルクKgaA アペキシゲン イムノビアAB ヴィアトリス アムジェン アストラゼネカPLC ブリストル・マイヤーズ スクイブ ノバルティスAG ファイザー ミリアド・ジェネティクス キヤノンメディカルシステムズ株式会社 富士フイルムホールディングス ボストン・サイエンティフィック ラファエルホールディングス(ラファエル・ファーマシューティカルズ) タイプ別セグメント イメージング 生検 超音波内視鏡 その他 用途別セグメント 病院 クリニック その他 地域別 北米 アメリカ カナダ 欧州 ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章：報告書のスコープ、世界の総市場規模を紹介。本章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章：膵臓がん診断メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章：タイプ別に様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性を網羅し、読者が異なる市場セグメントでブルーオーシャン市場を見つけるのを助ける。 第4章：用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。 第5章：地域レベルでの膵臓がん診断の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。 第6章：国別膵臓がん診断の収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロフィールを提供し、製品収益、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Pancreatic Cancer Diagnosis Product Introduction 1.2 Global Pancreatic Cancer Diagnosis Market Size Forecast 1.3 Pancreatic Cancer Diagnosis Market Trends & Drivers 1.3.1 Pancreatic Cancer Diagnosis Industry Trends 1.3.2 Pancreatic Cancer Diagnosis Market Drivers & Opportunity 1.3.3 Pancreatic Cancer Diagnosis Market Challenges 1.3.4 Pancreatic Cancer Diagnosis Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Pancreatic Cancer Diagnosis Players Revenue Ranking (2023) 2.2 Global Pancreatic Cancer Diagnosis Revenue by Company (2019-2024) 2.3 Key Companies Pancreatic Cancer Diagnosis Manufacturing Base Distribution and Headquarters 2.4 Key Companies Pancreatic Cancer Diagnosis Product Offered 2.5 Key Companies Time to Begin Mass Production of Pancreatic Cancer Diagnosis 2.6 Pancreatic Cancer Diagnosis Market Competitive Analysis 2.6.1 Pancreatic Cancer Diagnosis Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Pancreatic Cancer Diagnosis Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pancreatic Cancer Diagnosis as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Imaging 3.1.2 Biopsy 3.1.3 Endoscopic Ultrasound 3.1.4 Others 3.2 Global Pancreatic Cancer Diagnosis Sales Value by Type 3.2.1 Global Pancreatic Cancer Diagnosis Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Pancreatic Cancer Diagnosis Sales Value, by Type (2019-2030) 3.2.3 Global Pancreatic Cancer Diagnosis Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Clinic 4.1.3 Others 4.2 Global Pancreatic Cancer Diagnosis Sales Value by Application 4.2.1 Global Pancreatic Cancer Diagnosis Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Pancreatic Cancer Diagnosis Sales Value, by Application (2019-2030) 4.2.3 Global Pancreatic Cancer Diagnosis Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Pancreatic Cancer Diagnosis Sales Value by Region 5.1.1 Global Pancreatic Cancer Diagnosis Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Pancreatic Cancer Diagnosis Sales Value by Region (2019-2024) 5.1.3 Global Pancreatic Cancer Diagnosis Sales Value by Region (2025-2030) 5.1.4 Global Pancreatic Cancer Diagnosis Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Pancreatic Cancer Diagnosis Sales Value, 2019-2030 5.2.2 North America Pancreatic Cancer Diagnosis Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Pancreatic Cancer Diagnosis Sales Value, 2019-2030 5.3.2 Europe Pancreatic Cancer Diagnosis Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Pancreatic Cancer Diagnosis Sales Value, 2019-2030 5.4.2 Asia Pacific Pancreatic Cancer Diagnosis Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Pancreatic Cancer Diagnosis Sales Value, 2019-2030 5.5.2 South America Pancreatic Cancer Diagnosis Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Pancreatic Cancer Diagnosis Sales Value, 2019-2030 5.6.2 Middle East & Africa Pancreatic Cancer Diagnosis Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Pancreatic Cancer Diagnosis Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Pancreatic Cancer Diagnosis Sales Value 6.3 United States 6.3.1 United States Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.3.2 United States Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.4.2 Europe Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.5.2 China Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.5.3 China Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.6.2 Japan Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.7.2 South Korea Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.8.2 Southeast Asia Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.9.2 India Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.9.3 India Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 F Hoffmann-La Roche AG 7.1.1 F Hoffmann-La Roche AG Profile 7.1.2 F Hoffmann-La Roche AG Main Business 7.1.3 F Hoffmann-La Roche AG Pancreatic Cancer Diagnosis Products, Services and Solutions 7.1.4 F Hoffmann-La Roche AG Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.1.5 F Hoffmann-La Roche AG Recent Developments 7.2 Merck KgaA 7.2.1 Merck KgaA Profile 7.2.2 Merck KgaA Main Business 7.2.3 Merck KgaA Pancreatic Cancer Diagnosis Products, Services and Solutions 7.2.4 Merck KgaA Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.2.5 Merck KgaA Recent Developments 7.3 Apexigen 7.3.1 Apexigen Profile 7.3.2 Apexigen Main Business 7.3.3 Apexigen Pancreatic Cancer Diagnosis Products, Services and Solutions 7.3.4 Apexigen Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.3.5 Immunovia AB Recent Developments 7.4 Immunovia AB 7.4.1 Immunovia AB Profile 7.4.2 Immunovia AB Main Business 7.4.3 Immunovia AB Pancreatic Cancer Diagnosis Products, Services and Solutions 7.4.4 Immunovia AB Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.4.5 Immunovia AB Recent Developments 7.5 Viatris 7.5.1 Viatris Profile 7.5.2 Viatris Main Business 7.5.3 Viatris Pancreatic Cancer Diagnosis Products, Services and Solutions 7.5.4 Viatris Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.5.5 Viatris Recent Developments 7.6 Amgen 7.6.1 Amgen Profile 7.6.2 Amgen Main Business 7.6.3 Amgen Pancreatic Cancer Diagnosis Products, Services and Solutions 7.6.4 Amgen Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.6.5 Amgen Recent Developments 7.7 AstraZeneca PLC 7.7.1 AstraZeneca PLC Profile 7.7.2 AstraZeneca PLC Main Business 7.7.3 AstraZeneca PLC Pancreatic Cancer Diagnosis Products, Services and Solutions 7.7.4 AstraZeneca PLC Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.7.5 AstraZeneca PLC Recent Developments 7.8 Bristol-Myers Squibb 7.8.1 Bristol-Myers Squibb Profile 7.8.2 Bristol-Myers Squibb Main Business 7.8.3 Bristol-Myers Squibb Pancreatic Cancer Diagnosis Products, Services and Solutions 7.8.4 Bristol-Myers Squibb Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.8.5 Bristol-Myers Squibb Recent Developments 7.9 NovartisAG 7.9.1 NovartisAG Profile 7.9.2 NovartisAG Main Business 7.9.3 NovartisAG Pancreatic Cancer Diagnosis Products, Services and Solutions 7.9.4 NovartisAG Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.9.5 NovartisAG Recent Developments 7.10 Pfizer 7.10.1 Pfizer Profile 7.10.2 Pfizer Main Business 7.10.3 Pfizer Pancreatic Cancer Diagnosis Products, Services and Solutions 7.10.4 Pfizer Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.10.5 Pfizer Recent Developments 7.11 Myriad Genetics 7.11.1 Myriad Genetics Profile 7.11.2 Myriad Genetics Main Business 7.11.3 Myriad Genetics Pancreatic Cancer Diagnosis Products, Services and Solutions 7.11.4 Myriad Genetics Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.11.5 Myriad Genetics Recent Developments 7.12 Canon Medical Systems Corporation 7.12.1 Canon Medical Systems Corporation Profile 7.12.2 Canon Medical Systems Corporation Main Business 7.12.3 Canon Medical Systems Corporation Pancreatic Cancer Diagnosis Products, Services and Solutions 7.12.4 Canon Medical Systems Corporation Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.12.5 Canon Medical Systems Corporation Recent Developments 7.13 FUJIFILM Holdings Corporation 7.13.1 FUJIFILM Holdings Corporation Profile 7.13.2 FUJIFILM Holdings Corporation Main Business 7.13.3 FUJIFILM Holdings Corporation Pancreatic Cancer Diagnosis Products, Services and Solutions 7.13.4 FUJIFILM Holdings Corporation Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.13.5 FUJIFILM Holdings Corporation Recent Developments 7.14 Boston Scientific Corporation 7.14.1 Boston Scientific Corporation Profile 7.14.2 Boston Scientific Corporation Main Business 7.14.3 Boston Scientific Corporation Pancreatic Cancer Diagnosis Products, Services and Solutions 7.14.4 Boston Scientific Corporation Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.14.5 Boston Scientific Corporation Recent Developments 7.15 RafaelHoldings Inc.(Rafael Pharmaceuticals) 7.15.1 RafaelHoldings Inc.(Rafael Pharmaceuticals) Profile 7.15.2 RafaelHoldings Inc.(Rafael Pharmaceuticals) Main Business 7.15.3 RafaelHoldings Inc.(Rafael Pharmaceuticals) Pancreatic Cancer Diagnosis Products, Services and Solutions 7.15.4 RafaelHoldings Inc.(Rafael Pharmaceuticals) Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.15.5 RafaelHoldings Inc.(Rafael Pharmaceuticals) Recent Developments 8 Industry Chain Analysis 8.1 Pancreatic Cancer Diagnosis Industrial Chain 8.2 Pancreatic Cancer Diagnosis Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Pancreatic Cancer Diagnosis Sales Model 8.5.2 Sales Channel 8.5.3 Pancreatic Cancer Diagnosis Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Pancreatic Cancer Diagnosis was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030. Table of Contents1 Market Overview1.1 Pancreatic Cancer Diagnosis Product Introduction 1.2 Global Pancreatic Cancer Diagnosis Market Size Forecast 1.3 Pancreatic Cancer Diagnosis Market Trends & Drivers 1.3.1 Pancreatic Cancer Diagnosis Industry Trends 1.3.2 Pancreatic Cancer Diagnosis Market Drivers & Opportunity 1.3.3 Pancreatic Cancer Diagnosis Market Challenges 1.3.4 Pancreatic Cancer Diagnosis Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Pancreatic Cancer Diagnosis Players Revenue Ranking (2023) 2.2 Global Pancreatic Cancer Diagnosis Revenue by Company (2019-2024) 2.3 Key Companies Pancreatic Cancer Diagnosis Manufacturing Base Distribution and Headquarters 2.4 Key Companies Pancreatic Cancer Diagnosis Product Offered 2.5 Key Companies Time to Begin Mass Production of Pancreatic Cancer Diagnosis 2.6 Pancreatic Cancer Diagnosis Market Competitive Analysis 2.6.1 Pancreatic Cancer Diagnosis Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Pancreatic Cancer Diagnosis Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pancreatic Cancer Diagnosis as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Imaging 3.1.2 Biopsy 3.1.3 Endoscopic Ultrasound 3.1.4 Others 3.2 Global Pancreatic Cancer Diagnosis Sales Value by Type 3.2.1 Global Pancreatic Cancer Diagnosis Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Pancreatic Cancer Diagnosis Sales Value, by Type (2019-2030) 3.2.3 Global Pancreatic Cancer Diagnosis Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Clinic 4.1.3 Others 4.2 Global Pancreatic Cancer Diagnosis Sales Value by Application 4.2.1 Global Pancreatic Cancer Diagnosis Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Pancreatic Cancer Diagnosis Sales Value, by Application (2019-2030) 4.2.3 Global Pancreatic Cancer Diagnosis Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Pancreatic Cancer Diagnosis Sales Value by Region 5.1.1 Global Pancreatic Cancer Diagnosis Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Pancreatic Cancer Diagnosis Sales Value by Region (2019-2024) 5.1.3 Global Pancreatic Cancer Diagnosis Sales Value by Region (2025-2030) 5.1.4 Global Pancreatic Cancer Diagnosis Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Pancreatic Cancer Diagnosis Sales Value, 2019-2030 5.2.2 North America Pancreatic Cancer Diagnosis Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Pancreatic Cancer Diagnosis Sales Value, 2019-2030 5.3.2 Europe Pancreatic Cancer Diagnosis Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Pancreatic Cancer Diagnosis Sales Value, 2019-2030 5.4.2 Asia Pacific Pancreatic Cancer Diagnosis Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Pancreatic Cancer Diagnosis Sales Value, 2019-2030 5.5.2 South America Pancreatic Cancer Diagnosis Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Pancreatic Cancer Diagnosis Sales Value, 2019-2030 5.6.2 Middle East & Africa Pancreatic Cancer Diagnosis Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Pancreatic Cancer Diagnosis Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Pancreatic Cancer Diagnosis Sales Value 6.3 United States 6.3.1 United States Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.3.2 United States Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.4.2 Europe Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.5.2 China Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.5.3 China Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.6.2 Japan Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.7.2 South Korea Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.8.2 Southeast Asia Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Pancreatic Cancer Diagnosis Sales Value, 2019-2030 6.9.2 India Pancreatic Cancer Diagnosis Sales Value by Type (%), 2023 VS 2030 6.9.3 India Pancreatic Cancer Diagnosis Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 F Hoffmann-La Roche AG 7.1.1 F Hoffmann-La Roche AG Profile 7.1.2 F Hoffmann-La Roche AG Main Business 7.1.3 F Hoffmann-La Roche AG Pancreatic Cancer Diagnosis Products, Services and Solutions 7.1.4 F Hoffmann-La Roche AG Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.1.5 F Hoffmann-La Roche AG Recent Developments 7.2 Merck KgaA 7.2.1 Merck KgaA Profile 7.2.2 Merck KgaA Main Business 7.2.3 Merck KgaA Pancreatic Cancer Diagnosis Products, Services and Solutions 7.2.4 Merck KgaA Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.2.5 Merck KgaA Recent Developments 7.3 Apexigen 7.3.1 Apexigen Profile 7.3.2 Apexigen Main Business 7.3.3 Apexigen Pancreatic Cancer Diagnosis Products, Services and Solutions 7.3.4 Apexigen Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.3.5 Immunovia AB Recent Developments 7.4 Immunovia AB 7.4.1 Immunovia AB Profile 7.4.2 Immunovia AB Main Business 7.4.3 Immunovia AB Pancreatic Cancer Diagnosis Products, Services and Solutions 7.4.4 Immunovia AB Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.4.5 Immunovia AB Recent Developments 7.5 Viatris 7.5.1 Viatris Profile 7.5.2 Viatris Main Business 7.5.3 Viatris Pancreatic Cancer Diagnosis Products, Services and Solutions 7.5.4 Viatris Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.5.5 Viatris Recent Developments 7.6 Amgen 7.6.1 Amgen Profile 7.6.2 Amgen Main Business 7.6.3 Amgen Pancreatic Cancer Diagnosis Products, Services and Solutions 7.6.4 Amgen Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.6.5 Amgen Recent Developments 7.7 AstraZeneca PLC 7.7.1 AstraZeneca PLC Profile 7.7.2 AstraZeneca PLC Main Business 7.7.3 AstraZeneca PLC Pancreatic Cancer Diagnosis Products, Services and Solutions 7.7.4 AstraZeneca PLC Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.7.5 AstraZeneca PLC Recent Developments 7.8 Bristol-Myers Squibb 7.8.1 Bristol-Myers Squibb Profile 7.8.2 Bristol-Myers Squibb Main Business 7.8.3 Bristol-Myers Squibb Pancreatic Cancer Diagnosis Products, Services and Solutions 7.8.4 Bristol-Myers Squibb Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.8.5 Bristol-Myers Squibb Recent Developments 7.9 NovartisAG 7.9.1 NovartisAG Profile 7.9.2 NovartisAG Main Business 7.9.3 NovartisAG Pancreatic Cancer Diagnosis Products, Services and Solutions 7.9.4 NovartisAG Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.9.5 NovartisAG Recent Developments 7.10 Pfizer 7.10.1 Pfizer Profile 7.10.2 Pfizer Main Business 7.10.3 Pfizer Pancreatic Cancer Diagnosis Products, Services and Solutions 7.10.4 Pfizer Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.10.5 Pfizer Recent Developments 7.11 Myriad Genetics 7.11.1 Myriad Genetics Profile 7.11.2 Myriad Genetics Main Business 7.11.3 Myriad Genetics Pancreatic Cancer Diagnosis Products, Services and Solutions 7.11.4 Myriad Genetics Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.11.5 Myriad Genetics Recent Developments 7.12 Canon Medical Systems Corporation 7.12.1 Canon Medical Systems Corporation Profile 7.12.2 Canon Medical Systems Corporation Main Business 7.12.3 Canon Medical Systems Corporation Pancreatic Cancer Diagnosis Products, Services and Solutions 7.12.4 Canon Medical Systems Corporation Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.12.5 Canon Medical Systems Corporation Recent Developments 7.13 FUJIFILM Holdings Corporation 7.13.1 FUJIFILM Holdings Corporation Profile 7.13.2 FUJIFILM Holdings Corporation Main Business 7.13.3 FUJIFILM Holdings Corporation Pancreatic Cancer Diagnosis Products, Services and Solutions 7.13.4 FUJIFILM Holdings Corporation Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.13.5 FUJIFILM Holdings Corporation Recent Developments 7.14 Boston Scientific Corporation 7.14.1 Boston Scientific Corporation Profile 7.14.2 Boston Scientific Corporation Main Business 7.14.3 Boston Scientific Corporation Pancreatic Cancer Diagnosis Products, Services and Solutions 7.14.4 Boston Scientific Corporation Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.14.5 Boston Scientific Corporation Recent Developments 7.15 RafaelHoldings Inc.(Rafael Pharmaceuticals) 7.15.1 RafaelHoldings Inc.(Rafael Pharmaceuticals) Profile 7.15.2 RafaelHoldings Inc.(Rafael Pharmaceuticals) Main Business 7.15.3 RafaelHoldings Inc.(Rafael Pharmaceuticals) Pancreatic Cancer Diagnosis Products, Services and Solutions 7.15.4 RafaelHoldings Inc.(Rafael Pharmaceuticals) Pancreatic Cancer Diagnosis Revenue (US$ Million) & (2019-2024) 7.15.5 RafaelHoldings Inc.(Rafael Pharmaceuticals) Recent Developments 8 Industry Chain Analysis 8.1 Pancreatic Cancer Diagnosis Industrial Chain 8.2 Pancreatic Cancer Diagnosis Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Pancreatic Cancer Diagnosis Sales Model 8.5.2 Sales Channel 8.5.3 Pancreatic Cancer Diagnosis Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野の最新刊レポート
QYResearch 社の最新刊レポート本レポートと同じKEY WORD（）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/04 10:27 147.72 円 163.39 円 196.69 円 |